Thursday 5 March 2026

One To Watch

Century Therapeutics

A biotechnology company developing cell therapies in immuno-oncology, autoimmune and inflammatory diseases.

Company Overview

Want to Update your Company's Profile?


Latest Century Therapeutics News

Century’s triple-dose of news a ‘transformative milestone’
11 April 2024
Century Therapeutics inks deal with BMS on iPSC-derived allogeneic cell therapies
10 January 2022
BRIEF—Century Therapeutics founded with $250 million
1 July 2019
More Century Therapeutics news >


Today's issue

The three biggest EHS blind spots in pharma
Pharmaceutical
The three biggest EHS blind spots in pharma
5 March 2026
Pharmaceutical
Helus Pharma’s top-line Phase II data signal detection study for HLP004
5 March 2026
Pharmaceutical
Roche survey highlights daily burden of diabetes
5 March 2026
Pharmaceutical
Biologos appoints Hetal Patel as chief executive
5 March 2026
Pharmaceutical
Merck KGaA posts resilient 2025 results as cautious 2026 outlook weighs on shares
5 March 2026
Pharmaceutical
D-MNA results ‘decision-grade evidence of clinical activity’, Medicus says
5 March 2026
Pharmaceutical
Sanofi licenses rovadicitinib from Sino Biopharm in up to $1.5 billion deal
5 March 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze